Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, United States; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
Oliver Jonas
The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States
Casandra Chen
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, United States; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
Mikael L Rinne
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, United States; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
John G Doench
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, United States
Federica Piccioni
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, United States
Li Tan
Department of Cancer Biology, Dana Farber Cancer Institute, Boston, United States; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
Hai-Tsang Huang
Department of Cancer Biology, Dana Farber Cancer Institute, Boston, United States; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
Jinhua Wang
Department of Cancer Biology, Dana Farber Cancer Institute, Boston, United States; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
Young Jin Ham
Department of Cancer Biology, Dana Farber Cancer Institute, Boston, United States; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
Joyce O'Connell
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, United States; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
Patrick Bhola
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
Mihir Doshi
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, United States; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
Matthew Whitman
The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States
Michael Cima
The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States; Department of Materials Science, Massachusetts Institute of Technology, Cambridge, United States
Anthony Letai
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
David E Root
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, United States
Robert S Langer
The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, United States
Department of Cancer Biology, Dana Farber Cancer Institute, Boston, United States; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, United States; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States; Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States
Activating mutations involving the PI3K pathway occur frequently in human cancers. However, PI3K inhibitors primarily induce cell cycle arrest, leaving a significant reservoir of tumor cells that may acquire or exhibit resistance. We searched for genes that are required for the survival of PI3K mutant cancer cells in the presence of PI3K inhibition by conducting a genome scale shRNA-based apoptosis screen in a PIK3CA mutant human breast cancer cell. We identified 5 genes (PIM2, ZAK, TACC1, ZFR, ZNF565) whose suppression induced cell death upon PI3K inhibition. We showed that small molecule inhibitors of the PIM2 and ZAK kinases synergize with PI3K inhibition. In addition, using a microscale implementable device to deliver either siRNAs or small molecule inhibitors in vivo, we showed that suppressing these 5 genes with PI3K inhibition induced tumor regression. These observations identify targets whose inhibition synergizes with PI3K inhibitors and nominate potential combination therapies involving PI3K inhibition.